PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth similar to AGEN's 12.12%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-4.31%
Both reduce yoy D&A, with AGEN at -4.07%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-1173.94%
Negative yoy deferred tax while AGEN stands at 100.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-7.99%
Both cut yoy SBC, with AGEN at -2.66%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
214.02%
Slight usage while AGEN is negative at -230.01%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Both negative yoy AP, with AGEN at -218.81%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
259.96%
Growth well above AGEN's 124.25%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
1173.94%
Some yoy increase while AGEN is negative at -104.24%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
18.46%
Some CFO growth while AGEN is negative at -46.64%. John Neff would note a short-term liquidity lead over the competitor.
36.17%
CapEx growth well above AGEN's 22.20%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
Lower net investing outflow yoy vs. AGEN's 2133.66%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Both yoy lines negative, with AGEN at -51.83%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.